Digital Medicine
We work with founders to build companies leveraging AI, machine learning and data analytics to transform healthcare and medicine.
Our approach is evidence-based, rooted in rigorous scientific research and clinical validation and builds on Sofinnova's 50 years of experience in the life sciences sector.
| Close | Fund | AMT |
|---|---|---|
| 2023 | Sofinnova Digital Medicine I | $200 million |
Close: 2023
Fund: Sofinnova Digital Medicine I
AMT: $200 million
"We bring our experience in biological innovation coupled with powerful computing and AI capabilities to build deeply technical companies to product-market fit. This is what makes our approach unique."
"We designed this strategy to help founders leverage our knowledge of a highly-regulated and complex healthcare industry while drawing on the strengths of tech-industry approaches like rapid product iteration and swift commercialization."
The
Team
Companies
Fund iteration
Status
Deal lead
Related News
deepc and The AI Centre for Value-Based Healthcare enter partnership to accelerate and transform NHS adoption of radiology AI
Bioptimus and Proscia collaborate to accelerate AI innovation in scientific research and drug development for improved patient care
Video: Sofinnova Partners 2024 annual general meeting
deepc closes Series A extension to accelerate global deployment of healthcare AI, bringing total funding to $30m
Bioptimus launches H-optimus-0, the world's largest open-source AI foundation model for pathology